In this episode, Niklas sits down with attorneys Ian Huyett, who works on litigation and state-level health reform, and Andrew Ittleman, who represents FDA-regulated companies and litigated Regenerative Sciences v. FDA, to talk about where the FDA’s authority comes from and how it applies when a doctor treats a patient inside one state.
The conversation goes on to cover the 1938 law behind that authority, the 2014 Regenerative Sciences case, what changed after the Supreme Court’s Loper Bright decision, and how states and medical boards could share some of that power.
More about Ian Huyett’s work:
More about Andrew Ittleman’s work:
